Urology Alliance Clinical Research
Urology Alliance is a leader in clinical research. We offer trials because we believe this allows our patients and our practice to remain at the forefront of medicine.
What is clinical research? A clinical trial is a study that is carefully designed to answer specific questions about the safety and effectiveness of new medications, treatments, therapies or surgical techniques. At Urology Alliance, we participate in trials of all these types. All advances in modern medicine are made through the process of clinical research.
Why participate in a study? Clinical trials offer real benefits to current and future patients. A study will often offer access to a new treatment option that is not currently available to the public. These new options are usually designed to address a specific short-coming in current medical practice, and thus they often appeal to patients. You will receive very detailed and specific care from the research team before and during the trial. In addition to potentially receiving the investigational treatment, you have the added benefit of contributing to the future of medicine.
Are trials safe? All medical treatments and choices, including clinical trials, involve risks. There are, however, layers of oversight to help keep patients safe. Clinical trial protocols are nearly always approved by the FDA and by an IRB (institutional review board) before being offered to patients. These are independent entities that help ensure patient safety. Patients on a trial are cared for by CRCs (clinical research coordinators) who are experts at trial conduct and patient care and will work closely with each patient. Investigators on the trial are physicians or providers whose ultimate responsibility is to ensure patient safety and provide attentive care for any issues that arise.
At Urology Alliance, we believe these trials benefit our patients and that it is our obligation to offer the best treatments available. We believe this is what world-class urology and world-class clinical research look like.
See Clinical Research at Our Individual Sites
Studies Enrolling Across All Urology Alliance Sites
Prostate Cancer — Telix Bi-Pass (Coming Soon – Nov 2025)
(Diagnostic Trial) – Evaluating whether combining PET/imaging and MRI improves the detection of Prostate Cancer compared to Standard of Care.
Inclusion Criteria: Male participants aged 18 years or older with clinical suspicion of prostate cancer and no prior prostate biopsy.
More details coming soon.
This research study is available at the following locations: Urology Austin, Conrad Pearson, Southern Urology and Urology Associates
Prostate Cancer — Water IV
Comparing two surgical approaches for treating localized Prostate Cancer – Aquablation vs. Radical Prostatectomy
Inclusion Criteria: Male participants aged 45 years or older with a positive prostate biopsy with Grade Group 1–3, a PSA level of 20 or lower, and a prostate volume of 25 ml or greater.
This research study is available at the following locations: Urology Austin
Stress Incontinence in Prostate Cancer — ARID II
Device study for the Treatment of Post Prostatectomy Stress Urinary Incontinence in Males
Inclusion Criteria: Male participants aged 45 years or older who have been diagnosed with prostate cancer and scheduled for robotic assisted radical prostatectomy.
This research study is available at the following locations: Urology Austin and Conrad Pearson
Prostate Cancer — Astra Zeneca - EVO PAR (Coming Soon - Nov 2025)
A study to evaluate the impact of metastasis free survival with the addition of an investigational treatment for prostate cancer vs standard radiotherapy/ADPI treatment
Inclusion Criteria: Male participants aged 18 years or older with newly diagnosed high-risk prostate cancer and a confirmed BCRA1 or BCRA2 mutation.
More details coming soon.
This research study is available at the following locations: Urology Austin
Prostate Cancer — Novartis PMSAndARPI (Coming Soon - Nov 2025)
Evaluating the safety and effectiveness of the combination study treatment lutetium +marketed treatments vs. Lutetium alone
Inclusion Criteria: Participants with newly diagnosed metastatic castrate resistant prostate cancer who are currently on second-generation ARPI medications and have a positive PET PSMA scan.
More details coming soon.
This research study is available at the following locations: Urology Austin
Prostate Cancer — Bristol Myers Squibb-Recharge
Comparing BMS vs. Investigators choice in therapy comprising either Docetaxel or Second-Generation Androgen Receptor
Inclusion Criteria: Participants with newly diagnosed metastatic castrate resistant prostate cancer who are undergoing androgen deprivation therapy with testosterone and have previous treatment with APRI’s
This research study is available at the following locations: Urology Austin
Prostate Cancer — Telix - ProstAct (Coming Soon - Nov 2025)
Evaluating the effectiveness of experimental drug (Lutetium + Standard of Care) vs. (Standard of Care Alone)
Inclusion Criteria: Participants who have previous treatment with APRI’s and have documented metastatic progression.
More details coming soon.
This research study is available at the following locations: Conrad Pearson, Southern Urology and Urology Associates
Benign Prostatic Hyperplasia (BPH) — RAPID III - Rivermark
Evaluating the safety and Efficacy of the FloStent device in men suffering from Benign Prostatic Hyperplasia
Inclusion Criteria: Male participants aged 45 years or older with benign prostatic hyperplasia (BPH).
This research study is available at the following locations: Urology Austin, Conrad Pearson, Southern Urology, and Urology Associates
Benign Prostatic Hyperplasia (BPH) — iTind - Olympus
Study to compare the Nitinol (iTind) device vs. UroLift device for patients with Benign Prostatic Hyperplasia
Inclusion Criteria: Male participants aged 50 years or older with benign prostatic hyperplasia (BPH).
This research study is available at the following locations: Conrad Pearson
Benign Prostatic Hyperplasia (BPH) — ALPFA (Coming Soon - March 2026
Transurethral focused Ultrasound for the ablation of prostate tissue
Inclusion Criteria: Male participants with benign prostatic hyperplasia (BPH).
More details coming soon.
This research study is available at the following locations: Urology Austin, Conrad Pearson, Urology Associates
Bladder Cancer — Moonrise 2
Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
Inclusion Criteria: Participants aged 18 years or older with intermediate risk non muscle invasive bladder cancer.
This research study is available at the following locations: Urology Austin, Southern Urology, and Urology Associates
Bladder Cancer — Moonrise 3
Comparing TAR-210 to intravesc chemo in patients with bladder cancer
Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of papillary non-muscle invasive bladder cancer.
This research study is available at the following locations: Urology Austin and Conrad Pearson
Bladder Cancer — Interpath
Study of V940 in Combination with BCG Versus BCG Monotherapy and or V940 by itself in Participants with High-risk
Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of high-risk non-muscle invasive bladder cancer.
This research study is available at the following locations: Urology Austin, Conrad Pearson, Southern Urology, and Urology Associates
Bladder Cancer — Advance 2 - Protara
Evaluating the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer
Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of high-grade non-muscle invasive bladder cancer.
This research study is available at the following locations: Urology Austin, Conrad Pearson, and Urology Associates
Bladder Cancer — Core 008
Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
Inclusion Criteria: Participants aged 18 years or older with high-risk, high-grade non-muscle invasive bladder cancer (NMIBC) who are BCG naive, exposed and or unresponsive.
This research study is available at the following locations: Urology Austin
Bladder Cancer — Quilt 2.005
Study to evaluate either BCG +/- Anktiva in Patients with Bladder Cancer that have not received BCG
Inclusion Criteria: Participants aged 18 years or older with histologic confirmation of non-muscle invasive bladder cancer who are BCG naive.
This research study is available at the following locations: Urology Austin
Bladder Cancer — Engene - Legend
Evaluating the safety and tolerability of EG-70 in participants with non-muscle invasive bladder cancer
Inclusion Criteria: Participants aged 18 years or older with BCG unresponsive non-muscle invasive bladder cancer with CIS, with or without coexisting papillary Ta/T1 tumors.
This research study is available at the following locations: Urology Austin
